Company news
Werewolf Therapeutics, Inc. news in 2022
Werewolf Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors
August 31, 2022
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 10, 2022
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 9, 2022
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting
April 7, 2022
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights
March 23, 2022
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment
March 15, 2022
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
March 14, 2022